Torsten
Pharma
ArgenX
Belgium
Biography
Torsten Dreier has been developing antibodies for more than 20 years and progressed six antibody products from preclinical research into clinical trials. Prior to joining argenx, he was Director of Therapeutic Drug Development and Senior Director Preclinical Development at Ablynx NV, with overall responsibility for pharmacology, toxicology, bioanalytics and CMC as well as early clinical development. Between 1997-2003, Dr. Dreier worked as Director Preclinical Development at Micromet AG in Munich, Germany, on the preclinical characterization of recombinant antibodies and BiTEs® (bispecific T cell engagers).
Research Interest
Pharma
